Emblaveo Patent Expiration

Emblaveo is a drug owned by Abbvie Inc. It is protected by 7 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 15, 2032. Details of Emblaveo's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9695122 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)

Active
US8969566 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)

Active
US9284314 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)

Active
US8471025 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(6 years from now)

Active
US7112592 Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(9 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(5 years from now)

Active
US7612087 Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(1 year, 7 months from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Emblaveo's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Emblaveo's generic, the next section provides detailed information on ongoing and past EP oppositions related to Emblaveo patents.

Emblaveo's Oppositions Filed in EPO

Emblaveo has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 26, 2019, by Lederer & Keller Patentanwälte Partnerschaft Mbb. This opposition was filed on patent number EP17182561A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17182561A Nov, 2019 Lederer & Keller Patentanwälte Partnerschaft mbB Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Emblaveo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emblaveo's family patents as well as insights into ongoing legal events on those patents.

Emblaveo's Family Patents

Emblaveo has patent protection in a total of 55 countries. It's US patent count contributes only to 12.2% of its total global patent coverage. 24 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Emblaveo.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Emblaveo's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 15, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Emblaveo Generics:

There are no approved generic versions for Emblaveo as of now.





About Emblaveo

Emblaveo is a drug owned by Abbvie Inc. Emblaveo uses Avibactam Sodium; Aztreonam as an active ingredient. Emblaveo was launched by Abbvie in 2025.

Approval Date:

Emblaveo was approved by FDA for market use on 07 February, 2025.

Active Ingredient:

Emblaveo uses Avibactam Sodium; Aztreonam as the active ingredient. Check out other Drugs and Companies using Avibactam Sodium; Aztreonam ingredient

Dosage:

Emblaveo is available in powder form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.5GM BASE/VIAL;1.5GM/VIAL POWDER Prescription INTRAVENOUS